Carfilzomib is a second-generation, selective, and irreversible proteasome inhibitor. It is a synthetic analog of the natural product epoxomicin, optimized for improved pharmacological properties. The peptide epoxyketone pharmacophore specifically and covalently binds to the N-terminal threonine residues of the proteasome’s catalytic subunits, primarily inhibiting the chymotrypsin-like activity. Its discovery and development represented a significant advance over first-generation proteasome inhibitors like bortezomib, offering a distinct mechanism of irreversible binding and potentially improved tolerability profiles.
Carfilzomib holds major significance in oncology, particularly for the treatment of relapsed and refractory multiple myeloma. It was developed to overcome limitations of resistance and neuropathy associated with bortezomib. The FDA initially approved it in 2012 for patients with multiple myeloma who have received at least two prior therapies, and its indications have since expanded. Its role underscores the therapeutic importance of targeting the ubiquitin-proteasome pathway in hematologic malignancies.
Quick Facts
| Also Known As | PR-171, Kyprolis |
|---|---|
| Sequence | Single-letter: Mw is a tetrapeptide epoxyketone. Structure: (2S)-N-[(2S)-1-[[(2S)-4-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]pentyl]amino]-4-phenyl-1-oxobutan-2-yl]-2-[(2S)-2-[[2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethyl]amino]-4-methylpentanamido]-4-methylpentanamide |
| Molecular Formula | C40H57N5O7 |
| Molecular Weight | 719.9 Da |
| PubChem CID | 11556711 |
Research Parameters
| Half-Life | ~1 hour or less (rapid distribution and elimination) |
|---|---|
| Stability | Lyophilized powder is stable when stored as directed. After reconstitution with sterile water, the solution should be used immediately or stored at 2-8°C for up to 24 hours. Further dilution in infusion bags is stable for up to 36 hours at 2-8°C. |
| Solubility | Reconstituted with Sterile Water for Injection, then further diluted in 5% Dextrose Injection. |
| Vial Size | 60 mg |
| Storage (Lyophilized) | Store at 2-8°C. Protect from light. |
| Storage (Reconstituted) | Store at 2-8°C for up to 24 hours. Protect from light. Do not freeze. |
| Typical Research Dose | Clinical doses are in mg/m² body surface area. A typical dose after escalation is 27 mg/m², which translates to approximately 40-80 mg (40,000-80,000 mcg) per infusion for an average adult. |
| Cycle Parameters | In clinical research for myeloma, a common cycle is 28 days, with administration on days 1, 2, 8, 9, 15, and 16 (twice-weekly schedule). Treatment continues until disease progression or unacceptable toxicity. Weekly schedules (days 1, 8, 15 of a 28-day cycle) are also studied. |
| Amino Acid Count | 34 |
Mechanism of Action
Carfilzomib exerts its primary therapeutic effect through the selective and irreversible inhibition of the 20S proteasome, a large protein complex responsible for the degradation of intracellular proteins. This inhibition disrupts normal protein homeostasis, leading to the accumulation of polyubiquitinated proteins, endoplasmic reticulum stress, and ultimately the induction of apoptosis, particularly in rapidly dividing cells like myeloma cells.
Proteasome Inhibition: Carfilzomib contains an epoxyketone group that forms a morpholino ring via a dual covalent adduction with the catalytic N-terminal threonine residue (Thr1) of the 20S proteasome's β5 subunit. This irreversible binding potently inhibits the chymotrypsin-like activity of the proteasome.
Unfolded Protein Response (UPR) and ER Stress: Inhibition of proteasomal degradation leads to an accumulation of misfolded and damaged proteins within the endoplasmic reticulum (ER). This triggers the UPR, a stress-signaling pathway. If the stress is prolonged and cannot be resolved, the UPR switches from pro-survival to pro-apoptotic signaling.
Apoptosis Induction: The sustained ER stress activates downstream effectors like caspase-8, caspase-9, and the executioner caspase-3. It also leads to the upregulation of pro-apoptotic proteins (e.g., NOXA, BIM) and downregulation of anti-apoptotic proteins (e.g., MCL-1), tipping the balance toward programmed cell death.
Nuclear Factor-κB (NF-κB) Pathway Modulation: Proteasome inhibition prevents the degradation of the NF-κB inhibitor, IκBα, thereby sequestering NF-κB in the cytoplasm and inhibiting its transcriptional activity. This can suppress the expression of genes promoting cell survival, proliferation, and inflammation.
Research Applications
Oncology (Multiple Myeloma): Carfilzomib is a cornerstone therapy for relapsed/refractory multiple myeloma. Research demonstrates its efficacy in combination with dexamethasone, lenalidomide, or daratumumab, significantly improving progression-free survival and overall response rates compared to previous standards. Studies focus on its role in earlier lines of therapy and in high-risk patient populations.
Oncology (Other Hematologic Malignancies): Preclinical and clinical research explores carfilzomib's activity in other B-cell malignancies, including Waldenström macroglobulinemia, mantle cell lymphoma, and acute myeloid leukemia. Its mechanism is being investigated in contexts where proteasome dependency is a feature of the cancer cells.
Immunology and Autoimmunity: Research investigates proteasome inhibition as a strategy to modulate immune cell function. Studies examine carfilzomib's potential in reducing plasma cell-driven antibody production in autoimmune conditions, such as antibody-mediated rejection in transplantation or refractory autoimmune disorders like lupus.
Solid Tumors: While less effective than in hematologic cancers, research continues to evaluate carfilzomib in solid tumors, often in combination with other agents. The focus is on tumors with specific vulnerabilities to proteasome inhibition or ER stress induction.
Safety & Side Effects
The safety profile is primarily defined by clinical trials in humans. Common adverse events include fatigue, anemia, thrombocytopenia, nausea, diarrhea, dyspnea, and pyrexia. Notable serious side effects include cardiac events (heart failure, myocardial ischemia), acute renal failure, and tumor lysis syndrome. A characteristic toxicity is infusion-related reactions, which can include fever, chills, arthralgia, myalgia, and flushing; these often occur during or shortly after the first infusion. Peripheral neuropathy is reported but appears to be less frequent and severe compared to bortezomib. Pulmonary complications (pulmonary hypertension, diffuse alveolar hemorrhage) are rare but serious theoretical concerns. Animal toxicology studies have shown corresponding hematologic, cardiac, and renal toxicities at high doses.
Dosage Information
This information is derived from published clinical trial protocols and is for research reference only. It does not constitute medical advice.
Typical research (clinical trial) dosing for multiple myeloma involves intravenous infusion. A common regimen is 20 mg/m² on days 1 and 2 of cycle 1, escalated to 27 mg/m² thereafter, administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Infusions are typically given over 10-30 minutes. Other studied regimens include once-weekly administration (e.g., 70 mg/m² on days 1, 8, and 15 of a 28-day cycle) and combination therapies with different dosing schedules. The duration of treatment in studies continues until disease progression or unacceptable toxicity.
References
Kuhn, D.J., et al. 'Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.' Blood, 2007.
O'Connor, O.A., et al. 'Phase I-II study of the selective proteasome inhibitor carfilzomib in patients with hematologic malignancies.' Journal of Clinical Oncology, 2009.
Siegel, D.S., et al. 'A phase 2 study of single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.' Blood, 2012.
Stewart, A.K., et al. 'Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.' New England Journal of Medicine, 2015.
Moreau, P., et al. 'Once-weekly versus twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma.' The Lancet Oncology, 2019.
Wang, M., et al. 'Carfilzomib in relapsed or refractory multiple myeloma and renal impairment.' Journal of Hematology & Oncology, 2020.